XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1

The Company and Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2018 USD ($) Patients
Company And Summary Of Significant Accounting Policies Table [Line Items]
Revenues	$ 0
Concentrations of credit risk	$ 0
Phase 2B | GENETIC-AF Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients enrolled | Patients	267

X

- Definition

Company and summary of significant accounting policies.

+ References

No definition available.

+ Details

Name:	abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems
Namespace Prefix:	abio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of patients enrolled.

+ References

No definition available.

+ Details

Name:	abio_NumberOfPatientsEnrolled
Namespace Prefix:	abio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

+ Details

Name:	us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_HealthCareTrustFundAxis=abio_GENETICAFTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: